Audion Therapeutics touted positive results yesterday from a Phase I trial of the company’s hearing loss drug.
In 15 people with mild to moderate sensorineural hearing loss, Audion tested the safety and tolerability of its LY3056480 mediated Notch inhibitor. The drug is designed to regenerate the inner ear sensory hair cells that are lost over time.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.